Status:
COMPLETED
Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
National Center for Research Resources (NCRR)
Conditions:
Post Lung Transplantation
Eligibility:
All Genders
18+ years
Brief Summary
A fixed dosage regimen of voriconazole is routinely used for prophylaxis of aspergillosis in lung transplant patients at our institution. We hypothesize that use of a fixed dosage voriconazole regimen...
Detailed Description
Blood samples (5 mL) will be collected either from an existing indwelling intravenous catheter or via a catheter placed by a research nurse or phlebotomist. The samples will be centrifuged at 1,500 g ...
Eligibility Criteria
Inclusion
- Male or female lung transplant recipients, greater than 18 years old, who are initiated on the voriconazole prophylactic regimen (Figure 1) by their transplant physician as standard care will be eligible for inclusion in the study.
Exclusion
- Patients receiving voriconazole to treat an active fungal infection will be excluded. Patients that are concurrently receiving medications that are documented to affect voriconazole pharmacokinetics will be excluded. The agents included, but may not be limited to the following ;carbamazepine, phenytoin, omeprazole, rifabutin and rifampin.10
Key Trial Info
Start Date :
March 1 2004
Trial Type :
OBSERVATIONAL
End Date :
March 1 2006
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00177827
Start Date
March 1 2004
End Date
March 1 2006
Last Update
December 3 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213